Project Grant R01CA298232
Award Date
2/21/25
Completion Date
1/31/30
Dollars Obligated
$546K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $647,118 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate the role of the EYA3/PP2A pathway in regulating metastasis in triple negative breast cancer (TNBC). The primary awardee, the University of Colorado-Denver, will conduct studies to determine the molecular mechanisms by which the EYA3-NF-κB axis enhances TNBC metastasis, and how EYA3 regulates NF-κB signaling through its interaction with the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to elucidate the role of B and T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The $226,504 project, awarded on December 2, 2024 and running through November 30, 2026, will utilize a MADM mouse genetic system to study immune responses during the pre-malignant progression of TNBC. The research will perform spatial profiling, flow analysis,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $661,072 to Northwestern University to develop a first-in-class small molecule inhibitor targeting the USP22 oncogene for the treatment of triple negative breast cancer. The goal is to create a novel therapeutic with both chemo-targeting and immuno-activating properties that can also target cancer stem cells. This work aims to address critical challenges in cancer therapy,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The key objectives are to: 1) Study the genomic and phenotypic evolution of metastatic precursor cells during dissemination, 2) Investigate gene expression...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University provides $622,329 to conduct research aimed at modulating the growth, progression, and metastasis of triple-negative breast cancer (TNBC) by inhibiting the MDA-9 protein. The key objectives are to: 1) formulate a small molecule inhibitor of MDA-9 called PDZ1I-Nano for clinical use and characterize its non-cell-autonomous anti-tumor effects, particularly on...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) totaling $180,632.00 to the University of Pittsburgh to study methods for inhibiting breast cancer metastasis. The key objectives of this initiative are to: Discover and validate compounds that can effectively block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this engulfment process has been linked to increased tumor aggressiveness and metastatic potential. The...
The National Cancer Institute (NCI) awarded a $667,792 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Chicago. The five-year grant, running from June 1, 2024 to May 31, 2029, will fund research to develop "ultra-potent, pharmacologically stable" synthetic transcriptional repressors (STRs) that can directly inhibit the oncogenic activity of the transcription factors XBP1 and HIF1A. These targets are critical for the survival and growth of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $211,125 to Embiosys Inc. to develop a wearable, non-invasive treatment device for metastatic triple-negative breast cancer (TNBC). The goal is to combine this novel induced electric field (IEF) therapy with standard-of-care chemotherapies to improve outcomes for TNBC patients, particularly those who are ineligible for chemo-immunotherapy combinations. The 2-year project,...
The University of Wisconsin System has been awarded a $619,764 Project Grant from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program. The grant aims to develop multi-faceted strategies to enhance the treatment efficacy of a platelet-mediated immune checkpoint inhibitor delivery system (P-APDL1) against triple-negative breast cancer (TNBC). Key strategies include: (1) increasing the tumor-selective accumulation of P-APDL1 by triggering local thrombus formation...
This federal Project Grant award for $781,436 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to optimize anti-NMDAR antibodies for the treatment of triple-negative breast cancer (TNBC). Specifically, the award aims to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen candidate anti-NMDAR antibodies using cryo-EM to identify structural changes that drive neurological toxicity, and 3) evaluate the therapeutic...